Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BIVI - BIOVIE INC.

IEX Last Trade
2.235
-0.005   -0.224%

Share volume: 9,287
Last Updated: Thu 26 Dec 2024 08:30:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$2.24
-0.01
-0.22%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 20%
Dept financing 50%
Liquidity 14%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.37%
1 Month
-23.76%
3 Months
93.69%
6 Months
367.39%
1 Year
65.38%
2 Year
-66.46%
Key data
Stock price
$2.24
P/E Ratio 
0.00
DAY RANGE
$2.10 - $2.29
EPS 
$0.00
52 WEEK RANGE
$0.33 - $7.50
52 WEEK CHANGE
$76.95
MARKET CAP 
170.040 M
YIELD 
N/A
SHARES OUTSTANDING 
61.166 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,207,701
AVERAGE 30 VOLUME 
$1,393,397
Company detail
CEO: Cuong V. Do
Region: US
Website: bioviepharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

BioVie Inc. engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trials for Alzheimer's, Parkinson's and multiple myeloma and prostate cancer.

Recent news